Sign in to view content

Treatment Response to Antioxidant Supplementation Based on CFH and ARMS2Â Genetic Risk Allele Number in AREDS Patients With No AMD at Baseline

Carl C. Awh, MD, FASRS

Video
Published 2016

Related

The OASIS Trial: Natural History of Symptomatic Vitreomacular Adhesion
Joseph M. Coney, MD, FASRS
Annual Meeting Talks
2016
Precision Subretinal Delivery for Cell and Gene Therapy
Allen C Ho, MD FASRS
Updates from the Field
2019
Is the Choroid Driving the Development of Cystoid Macular Edema in Eyes With Retinitis Pigmentosa?
David Sarraf, MD
Annual Meeting Talks
2019

Category: AMD-Non-Neovascular

See more